Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer

dc.contributor.authorMolina Alejandre, Marta
dc.contributor.authorMartínez Toledo, Cristina
dc.contributor.authorSierra Rodero, Belén
dc.contributor.authorCalvo, Virginia
dc.contributor.authorCollazo Lorduy, Ana
dc.contributor.authorDiz Taín, Pilar
dc.contributor.authorSequero López, Silvia
dc.contributor.authorVázquez Estévez, Sergio
dc.contributor.authorMielgo, Xabier
dc.contributor.authorMartinez Banaclocha, Natividad
dc.contributor.authorGonzález Larriba, Jose Luís
dc.contributor.authorSánchez Hernández, Alfredo
dc.contributor.authorEstival, Anna
dc.contributor.authorCoves Sarto, Juan
dc.contributor.authorNadal, Ernest
dc.contributor.authorBernabé, Reyes
dc.contributor.authorPonce Aix, Santiago
dc.contributor.authorGarcía Grande, Aránzazu
dc.contributor.authorMedina Valdivieso, Soledad
dc.contributor.authorMañas Mora, Elisa
dc.contributor.authorMoreno-alonso, Elena
dc.contributor.authorGil González, Ángeles
dc.contributor.authorGutiérrez Escobedo, Juan Manuel
dc.contributor.authorPeña Cabia, Silvia
dc.contributor.authorMegías, Diego
dc.contributor.authorBlanco, Mariola
dc.contributor.authorCruz Bermúdez, Alberto
dc.contributor.authorProvencio, Mariano
dc.date.accessioned2026-06-30T14:32:35Z
dc.date.available2026-06-30T14:32:35Z
dc.date.issued2026-05-20
dc.date.updated2026-06-30T08:13:47Z
dc.description.abstractBackground Immunotherapy (IO) has improved prognosis of non-small cell lung cancer (NSCLC); however, some patients experience primary IO resistance (PIR). CXCL13 could be a promising PIR biomarker due to its role in antitumor immune responses. Methods 177 patients with stage IV NSCLC receiving IO from the observational, multicenter, real-world study BLI-O were included from 15 centers in Spain. CXCL13 and 39 other cytokines were measured in 158 baseline (BS1) and 98 post-first-cycle of IO (BS2) plasma samples. Additionally, peripheral T and B cell BS2 immunophenotypes were determined. CXCL13 levels were also measured in plasma samples from 38 stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy from the NADIM II trial (NCT03838159). PIR was defined as disease progression within 3 months in non-surgical cases or incomplete pathological response in surgical cases. Results Metastatic PIR patients had higher CXCL13 plasma levels compared to non-PIR patients, especially in BS2 samples, and exhibited a greater increase of CXCL13 levels after the first cycle of IO. Patients with high BS2 CXCL13 levels showed shorter PFS (p = 0.0002) and OS (p = 0.0007). Females showed a lower percentage of high CXCL13 cases compared to male cases. CXCL13 did not influence the growth of NSCLC cell lines in vitro. Moreover, the expression of the CXCL13/CXCR5 axis was restricted to the immune compartment of tumors. Plasmatic CXCL13 levels were not associated with PD-L1 TPS expression nor TLS density in tumor tissue. However, at systemic level, patients with high CXCL13 levels exhibited impaired B and T cell phenotypes, along with elevated levels of inflammatory cytokines, after first IO cycle. Finally, high BS2 CXCL13 levels in resectable cases were also associated with PIR. Conclusions Elevated CXCL13 levels after the first cycle of IO are associated with PIR and an altered peripheral immune profile in NSCLC, supporting its potential as a prognostic biomarker in these patients.
dc.format.extent15 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2050-7771
dc.identifier.pmid42163420
dc.identifier.urihttps://hdl.handle.net/2445/230312
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s40364-026-00929-9
dc.relation.ispartofBiomarker Research, 2026, vol. 14, num. 1
dc.relation.urihttps://doi.org/10.1186/s40364-026-00929-9
dc.rightscc by-nc-nd (c) Molina Alejandre, Marta et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationCàncer de pulmó
dc.subject.classificationCitotoxicitat per mediació cel·lular
dc.subject.otherLung cancer
dc.subject.otherCell-mediated cytotoxicity
dc.titlePlasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
s40364-026-00929-9.pdf
Mida:
4.41 MB
Format:
Adobe Portable Document Format